ProfileGDS5678 / 1415923_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 80% 82% 82% 81% 81% 79% 84% 86% 85% 77% 82% 79% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9124882
GSM967853U87-EV human glioblastoma xenograft - Control 25.6298680
GSM967854U87-EV human glioblastoma xenograft - Control 36.0085382
GSM967855U87-EV human glioblastoma xenograft - Control 46.0467282
GSM967856U87-EV human glioblastoma xenograft - Control 55.9001381
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6160881
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.3302279
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1326384
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5543686
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3704485
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2021377
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9382882
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5014579
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7901881